, June 30, 2023 /PRNewswire/ — Mesircompany based in Spain and usaConvened the 2nd Annual Meeting of I3LUNG, dedicated to the design and management of strategic clinical trials in oncology. This event brings together all international collaborators. I3LUNG project We share advances in artificial intelligence (AI) applied to lung cancer.
The project has been approved by the European Commission and under the Horizon Europe programme, €10 million. The program aims to promote research and innovation in order to achieve the Sustainable Development Goals and promote the competitiveness of the European Union.
The 16 participants of I3LUNG, including MEDSIR, Europe, Israeland usaaims to improve and personalize the treatment of metastatic non-small cell lung cancer, the most common form of lung cancer subtype. Although immunotherapy (IO) is the treatment of choice for many of these patients, only her 30–50% of treated patients benefit from her IO in the long term. Therefore, patients who are likely to respond better to this treatment should be selected.
I3LUNG is the cutting edge for clinical decision making, empowering physicians and patients to select optimal treatment plans through AI that analyzes and interprets the complexities of omics and clinical data that contribute to response to treatment with IO. We aim to create a tool for This is expected to optimize patient care and reduce treatment costs for the healthcare system.
MEDSIR Scientific Director Alicia Garcia said: “In addition to developing new therapeutic guidelines in the treatment of lung cancer, we hope that this effort will facilitate the application of digital diagnostic tools in European oncology research. It will allow us to apply our results and methodology to other types of cancer.”
About Medicer
Founded in 2012, MEDSIR works closely with partners to drive innovation in oncology research. The company manages all aspects of clinical trials from study design to publication, providing proof-of-concept support and a strategic approach to enable research partners to experience the best of both industry-based clinical research and investigator-initiated trials. I will help you.
To advance independent cancer research worldwide, MEDSIR has formed a strategic alliance with Oncoclinics, the world’s leading oncology group. Brazil has the greatest research potential in south america.
www.medsir.org
sauce mesir
